
Seventure bolsters investment committee
Venture house Seventure Partners has appointed Danilo Casadei Massari and Thomas Werner to the investment committee for its Health for Life Capital fund.
Seventure's Health for Life Capital fund reached a second close on €100m earlier this year. The life sciences fund has a specific focus on nutrition, resulting in its backing by dairy business Danone. Health for Life Capital explores opportunities linked to research involving the microbiome, which is the aggregate of microorganisms present in the human body.
Casadei Massari and Werner will work on identifying new investment opportunities, and more generally advise the VC on its strategy in the microbiome field.
Casadei Massari is an entrepreneur and has held a number of roles in the pharmaceutical field. He notably founded and led CM&D Pharma, a medical food company that was sold to Nestlé Health Science in 2011. Prior to that, Casadei Massari was vice president at Madaus Group, CEO of Madaus Italy and held several board appointments.
Werner specialises in advising businesses in the healthcare and nutrition sectors, holding executive and non-executive board positions for various companies. These include Basilea Pharmaceutica, Skyepharma and BSN Medical. Werner has also acted as managing director at GlaxoSmithKline (GSK) Germany and senior vice president at GSK. He was also managing director at Bristol-Myers Squibb Germany.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater